Vidarbha News

Glaucoma Competitive Landscape Report 2023 (Updated)

 Breaking News
  • No posts were found

Glaucoma Competitive Landscape Report 2023 (Updated)

February 26
18:05 2024
Glaucoma Competitive Landscape Report 2023 (Updated)

DelveInsight’s, “Glaucoma Competitive Landscape 2023” report provides comprehensive insights about 45+ Glaucoma companies and 50+ drugs in Glaucoma Competitive landscape. It covers the Glaucoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Glaucoma Competitive Landscape Report

  • DelveInsight’s Glaucoma report depicts a robust space with 45+ Glaucoma companies working to develop 50+ pipeline therapies for Glaucoma treatment.
  • The leading Glaucoma Companies working in the market include Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Ocuphire Pharma, HK inno.N, VivaVision Biotech, Qlaris Bio, Future Medicine, PolyActiva Pty Ltd, Theratocular Biotek, Whitecap Biosciences, JeniVision, AbbVie, Noveome Biotherapeutics, and others.
  • Promising Glaucoma therapies in the various stages of development include rhNGF, Aflibercept (Eylea, BAY 86-5321), OPA-6566, Latanoprost, TO-O-1001, ONL1204 Ophthalmic solution (Dose A), and others.
  • December 2023: Laboratorios Sophia S.A de C.V. announced a study of Phase 3 clinical trials for PRO-122, Timolol eye drops, Dorzolamide-Timolol Ophthalmic and Krytantek. A Non-inferiority in the Intraocular Pressure Decrease of the Preservative-free Ophthalmic Solution PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma.

 

Request a sample and discover the recent advances in Glaucoma Drugs @ Glaucoma Competitive Landscape Report

 

The Glaucoma report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Glaucoma report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

 

Glaucoma Overview

Glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma and narrow-angle glaucoma/angle-closure glaucoma. The “angle” in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.

 

Find out more about Glaucoma Analytical Perspective: In-depth Commercial Assessment @ Glaucoma Collaboration Analysis by Companies

 

Glaucoma Companies and Therapies

  • Allergan: DURYSTA 
  • Sun Pharma Advanced Research Company Limited: XELPROS
  • Nicox Ophthalmics: NCX 470
  • Tarsier Pharma: TRS01
  • Qlaris Bio: QLS-101
  • Noveome Biotherapeutics: ST266

 

Glaucoma Competitive Landscape

The Glaucoma report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

Glaucoma Report Assessment

  • Company Analysis
  • Glaucoma Therapeutic Assessment
  • Glaucoma Pipeline Assessment
  • Inactive Glaucoma Drugs Assessment
  • Glaucoma Unmet Needs

 

Learn more about the emerging Glaucoma Competitive Landscape @ Glaucoma Market Drivers and Barriers, Unmet Needs

 

Scope of the Glaucoma Competitive Landscape Report

  • Coverage- Global
  • Glaucoma Companies- Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Ocuphire Pharma, HK inno.N, VivaVision Biotech, Qlaris Bio, Future Medicine, PolyActiva Pty Ltd, Theratocular Biotek, Whitecap Biosciences, JeniVision, AbbVie, Noveome Biotherapeutics, and others.
  • Glaucoma therapies- rhNGF, Aflibercept (Eylea, BAY 86-5321), OPA-6566, Latanoprost, TO-O-1001, ONL1204 Ophthalmic solution (Dose A), and others.
  • Glaucoma Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type

 

Dive deep into rich insights for new drugs for Glaucoma Product Developmental Activities, Visit @ Glaucoma Research and Development Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Glaucoma: Overview
  4. Glaucoma -Analytical Perspective: In-depth Commercial Assessment
  5. Competitive Landscape
  6. Therapeutic Assessment
  7. Glaucoma: Company and Product Profiles (Marketed Therapies)
  8. Allergan
  9. DURYSTA
  10. Glaucoma: Company and Product Profiles (Pipeline Therapies)
  11. Late Stage Products (Phase III)
  12. Nicox Ophthalmics
  13. NCX 470
  14. Drug profiles in the detailed report…..
  15. Mid Stage Products (Phase II)
  16. Qlaris Bio
  17. QLS-101
  18. Drug profiles in the detailed report…..
  19. Early Stage Products (Phase I)
  20. Noveome Biotherapeutics
  21. ST266
  22. Drug profiles in the detailed report…..
  23. Preclinical and Discovery Stage Products
  24. Company Name
  25. Product Name
  26. Drug profiles in the detailed report…..
  27. Inactive Products
  28. Glaucoma- Unmet needs
  29. Glaucoma Market drivers and barriers
  30. Appendix

 

For further information on the Glaucoma Report @ Glaucoma Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Categories